Aufklappen
Schliessen
Branche GesundheitswesenAktienmarkt Sonstige |
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
| Leser | Medien | |
|---|---|---|---|---|
| 04.03. | Immunovia Publishes the Annual Report for the Financial Year 2018 | 2 | PR Newswire | |
| LUND, Sweden, March 4, 2019 /PRNewswire/ -- Immunovia has today published the annual report for 2018 in Swedish. It is available on Immunovia's website.
Mats Grahn, CEO, comments: "We... ► Artikel lesen | ||||
| IMMUNOVIA Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten! | LYNX | |||
► Artikel lesen | ||||
| 04.03. | Immunovia Provides an Update on the Optimization Work to Meet the Expected Performance for Commercialization of IMMray PanCan-d | 2 | PR Newswire | |
| LUND, SWEDEN, March 4, 2019 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia") today announced an update on the optimization process to refine the algorithms and eliminate any potential variations... ► Artikel lesen | ||||
| 15.02. | BRIEF-Immunovia Q4 Pretax Loss Widens To SEK 25.7 Mln | 1 | Reuters.com | |
► Artikel lesen | ||||
| 14.02. | Immunovia Full Year Report, January-December 2018 | 2 | PR Newswire | |
| STOCKHOLM, Feb. 14, 2019 /PRNewswire/ --
Throughout 2018, we continued to build on our mission to develop and validate accurate bloodbased diagnostic tests that can make a real and... ► Artikel lesen | ||||
| 14.02. | Immunovia to Participate in Upcoming Investor Conferences in March | 1 | PR Newswire | |
| LUND, Sweden, Feb. 14, 2019 /PRNewswire/ --
Immunovia AB today announced that Mats Grahn, Chief Executive Officer, will participate and host one-on-one investor meetings at the following... ► Artikel lesen | ||||
| 12.02. | Invitation to Presentation of Immunovia's Full Year Report 2018 on February 14, 2019 | 2 | PR Newswire | |
| LUND, Sweden, Feb. 12, 2019 /PRNewswire/ --
Immunovia invites to a teleconference (in English) for investors, analysts and media on February 14, at 5:30 - 6:30 p.m. CET. Immunovia will... ► Artikel lesen | ||||
| 12.02. | Immunovia AB Announces Appointment of Senior Director of Investor Relations | 2 | PR Newswire | |
| LUND, Sweden, Feb. 12, 2019 /PRNewswire/ --
(Nasdaq Stockholm: IMMNOV), to strengthen IR and shareholder communication Immunovia today announced that Julie Silber has joined as Director... ► Artikel lesen | ||||
| 13.11.18 | Immunovia Invited to Present at Jefferies 2018 London Healthcare Conference | 1 | PR Newswire | |
| LUND, Sweden, Nov. 13, 2018 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), today announced that the Company has been invited to present at the Jefferies 2018 London Healthcare Conference... ► Artikel lesen | ||||
| 07.11.18 | Immunovia Interim Report January-September 2018 | 2 | PR Newswire | |
| STOCKHOLM, Nov. 7, 2018 /PRNewswire/ -- Immunovia's IMMray platform for blood-based biomarker signatures offers exciting new opportunities to develop accurate diagnostic tests that can detect... ► Artikel lesen | ||||
| 06.11.18 | Immunovia Sponsors Primary Care Educational Symposium at Fenway Park in Honor of World Pancreatic Cancer Day | 1 | PR Newswire | |
| MARLBOROUGH, Massachusetts, Nov. 6, 2018 /PRNewswire/ -- On November 15, 2018 Immunovia will sponsor a unique educational symposium for primary care clinicians in honor of World Pancreatic... ► Artikel lesen | ||||
| 05.11.18 | Invitation to Presentation of Immunovia's Interim Report January-September 2018 on November 7, 2018 | 4 | PR Newswire | |
| LUND, Sweden, Nov 5, 2018 /PRNewswire/ -- Immunovia will publish the company's interim report for the period January-September 2018 on Wednesday, November 7, at 08:30 a.m. CET.
Immunovia... ► Artikel lesen | ||||
| 26.10.18 | Immunovia AB (Publ) Nomination Committee Appointed for AGM 2019 | 1 | PR Newswire | |
| According to the instruction that was adopted at the Immunovia AB (Publ) AGM May 3 2018, the nomination committee should consist of four members
LUND, Sweden, Oct. 26, 2018 /PRNewswire/... ► Artikel lesen | ||||
| 08.10.18 | Immunovia Announces Strategic Focus Centered on IMMray Blood-based Biomarker Signatures for Rheumatoid Arthritis Within Autoimmunity | 7 | PR Newswire | |
| LUND, Sweden, Oct. 8, 2018 /PRNewswire/ --Encouraged by the promising discovery study results previously reported, Immunovia's prime focus in autoimmunity testing will be to develop IMMray... ► Artikel lesen | ||||
| 04.10.18 | Immunovia PanFAM-1 Clinical Trial now Available on ClinicalTrials.gov, the Largest Clinical Trials Database in the World | 2 | PR Newswire | |
| LUND, Sweden, Oct. 4, 2018 /PRNewswire/ -- Immunovia has developed a blood based biomarker signature for early detection of pancreatic cancer called IMMray PanCan-d. To validate IMMray PanCan-d... ► Artikel lesen | ||||
| 28.09.18 | Invitation to Conference Call Regarding Immunovia's Autoimmune Diseases Strategy on October 8, 2018 | 5 | PR Newswire | |
| Immunovia invites to a teleconference (in English) for investors, analysts and media on October 8, 2018 at 3:00 - 4:00 p.m CET
LUND, Sweden, Sept. 28, 2018 /PRNewswire/ -- Immunovia... ► Artikel lesen | ||||
| 24.08.18 | Immunovia Interim Report, January-June 2018 | 5 | PR Newswire | |
| STOCKHOLM, Aug. 24, 2018 /PRNewswire/ -- "On 3 April, trading in Immunovia's shares started on NASDAQ Stockholm's main market, where we are listed in the Mid Cap segment. During the second... ► Artikel lesen | ||||
| 23.08.18 | Invitation to presentation of Immunovia's Interim Report January-June 2018 and Comments to the Previously Published Autoimmunity Study Results | 2 | PR Newswire | |
| LUND, Sweden, Aug. 23, 2018 /PRNewswire/ -- Immunovia will publish the company's interim report for the period January-June 2018 on Friday, August 24, at 08:30 a.m. CET.
Immunovia invites... ► Artikel lesen | ||||
| 09.08.18 | Immunovia's Blood-based IMMray Biomarker Array Provides Highly Accurate Diagnosis of non-small Cell Lung Cancer in a New Collaborative Study | 61 | PR Newswire | |
| LUND, Sweden, Aug 9, 2018 /PRNewswire/ -- Immunovia AB announced today that in a new collaborative study with a major global pharma company, Immunovia ´s innovative blood-based testing platform... ► Artikel lesen | ||||
| 03.08.18 | Karolinska Institutet Participates in Immunovia's PanFAM-1 Prospective Clinical Study for Early Detection of Pancreatic Cancer Using Blood-based Test | 5 | PR Newswire | |
| Prospects rise for world's first national screening program.
STOCKHOLM and LUND, SWEDEN, Aug 3, 2018 /PRNewswire/ --
Immunovia AB today announced that the Karolinska Institutet... ► Artikel lesen | ||||
| 08.06.18 | Immunovia has Completed a Directed Share Issue of Approximately SEK 324 Million | 9 | PR Newswire | |
| STOCKHOLM, June 8, 2018 /PRNewswire/ --
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA... ► Artikel lesen | ||||
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | |
|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 38,00 | +0,16 % | Siemens Healthineers hat Geburtstag | |
| Die seit einem Jahr von Siemens abgespaltene Tochter Healthineers feiert heute ihr Börsendebüt. Jetzt träumt man sogar von einem Aufstieg in den DAX. Am 16. März 2018 kam Siemens Healthineers mit einem... ► Artikel lesen | ||||
| ECKERT & ZIEGLER | 85,40 | -0,23 % | adesso, Allgeier, Cyan, Datagroup, Eckert & Ziegler, Fabasoft, Pva Tepla, S&T, Singulus und Vectron im Fokus - Wochenupdate KW 11/2019 | |
| Im wikifolio "Top Pics of the Year" soll eine Auswahl von 10 Einzeltiteln zusammengestellt werden, die meines Erachtens für das jeweilige Jahr die größten Renditechancen versprechen. Der Schwerpunkt... ► Artikel lesen | ||||
| VITA 34 | 13,95 | +0,72 % | Vita 34: Umsatz macht Arbeit, Ergebnis macht Freude | |
| Hamburg (www.aktiencheck.de) - Vita 34-Aktienanalyse von Aktienanalyst Henrik Markmann von der Montega AG: Henrik Markmann, Aktienanalyst der Montega AG, rät in einer aktuellen Aktienanalyse weiterhin... ► Artikel lesen | ||||
| UMS UNITED MEDICAL SYSTEMS | 0,61 | +0,83 % | XFRA FRA: DELETION OF INSTRUMENTS FROM XETRA - 21.01.2019 | |
| The following instruments on XETRA do have their last trading day on 21.01.2019 Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 21.01.2019 ISIN Name CA0673963090 BARD VENTURES... ► Artikel lesen | ||||
| EVOFEM BIOSCIENCES | 3,07 | +0,99 % | Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q4 2018 Results - Earnings Call Transcript | |
► Artikel lesen | ||||
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von
Nachrichten • Aktienkurse • DAX • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer | Datenschutz • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage